Procter & Gamble 10-Qquarter ended 2026-09-30

Executive Summary

Procter & Gamble sells branded household and personal-care products to consumers worldwide, earning revenue through retailers and other distribution channels. It is investing in products and packaging while simplifying its brands, markets and supply chain, with Thorne extending its presence in premium supplements. Q1 FY2027 sales rose 4.0%, driven mainly by higher unit volume rather than pricing. Operating income grew only 1.4% as commodity costs and product investment absorbed much of that growth despite productivity savings. For investors, the opportunity is to turn volume growth into stronger earnings; the threat is that cost pressure and competition prevent those investments from paying off.

What's Happening in the Business

• Demand improved unevenly: Unit volume rose 2.4%, while favorable geographic mix and pricing added to sales growth. Fabric & Home Care grew primarily through volume and gained market share, supporting growth in P&G’s largest business.
• Health Care’s growth relied on pricing and mix, while volume fell 3%. Lower cough-and-cold incidence and product discontinuations contributed to weakness, and Oral Care lost market share. Baby, Feminine & Family Care also faced softer demand in some European categories and greater merchandising investment.
• Portfolio simplification continued: The June 2025 restructuring plan combines brand and market exits with manufacturing and supply-chain changes. Management targets ≈$2.0B of pretax costs over two years and up to 7,000 non-manufacturing overhead position reductions by the end of FY2027; quarterly charges were $192M.
• Premium wellness expansion: On 10/1/2026, P&G completed its $3.9B all-cash acquisition of Thorne, a North American vitamins, minerals and supplements brand. Thorne joins Personal Health Care, although management expects its initial contribution to consolidated results to be immaterial.

Key Financial Highlights

Q1 FY2027 covers the three months ended 9/30/2026; cash-flow figures cover the same period.

• Margin pressure: Gross margin fell 160 bp to 49.8%. Commodity costs and product-and-packaging investment each cost 140 bp, partly offset by manufacturing productivity, lower tariff costs and recoveries, and pricing. Lower overhead expense relative to sales softened the operating-margin decline.
• Cash conversion: Capital expenditures were $1.37B. Receivables and inventory used $938M combined, while payables supplied $1.15B; supplier-finance balances within payables increased to ≈$6.5B from ≈$6.2B.
• Shareholder returns: Repurchases of $1.25B accompanied a net reduction of 6.08M shares, or 0.3%, during the quarter. Dividends consumed another $2.60B.
• Acquisition funding: Total debt rose 14% to $38.9B, mainly through short-term borrowing ahead of Thorne’s purchase. Cash increased to $15.4B from $9.94B before the acquisition closed.

Risk Assessment

• Demand and pricing: Health Care’s volume decline, Oral Care share losses and Latin American Grooming distribution losses show that pricing and brand investment do not uniformly protect demand against competitors and lower-priced alternatives.
• Gillette valuation: Its indefinite-lived intangible carries $12.8B; weaker category growth, margins or valuation assumptions could trigger a material noncash impairment.
• Funding dependence: Debt due within one year reached $17.0B, while current liabilities exceeded current assets by $12.5B, making continued cash generation and financing access important after Thorne’s cash purchase.
• International exposure: More than half of sales come from outside the United States, exposing earnings and supply chains to currency movements, tariffs, sanctions and local demand weakness.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2026 10-K.

What to Watch

• Volume-led growth: Fabric & Home Care gained share and grew through volume; sustained gains would validate product investment, while slowing volume or share losses would weaken that case.
• Health Care demand: Volume fell despite sales growth, and Thorne enters results next quarter. Returning volume growth and stabilizing Oral Care share would indicate healthier demand; continued declines would leave growth dependent on pricing and mix.
• Restructuring economics: Management expects the remaining plan costs in FY2027. Success means narrower margin pressure while sales hold up; savings accompanied by shrinking sales would suggest portfolio cuts are damaging the business.
• Post-acquisition financing: Short-term borrowing increased before Thorne closed. Subsequent filings will show whether operating cash reduces that borrowing or shareholder distributions keep refinancing needs elevated.